The current study illustrated that miR-653-5p restrained RA progression through targeting FGF2 and inactivation of the Wnt/β-catenin pathway, indicating that miR-653-5p may be an effective treatment target for RA. Here, FGF2 is linked to rheumatoid arthritis.